scholarly journals The Current Status of Cytomegalovirus (CMV) Prevalence in the MENA Region: A Systematic Review

Pathogens ◽  
2019 ◽  
Vol 8 (4) ◽  
pp. 213 ◽  
Author(s):  
Al Mana ◽  
Yassine ◽  
Younes ◽  
Al-Mohannadi ◽  
Al-Sadeq ◽  
...  
Keyword(s):  
Web Of Science ◽  
Severe Disease ◽  
The United States ◽  
World Health ◽  
Current Status ◽  
Inclusion Criteria ◽  
Mena Region ◽  
Scientific Databases ◽  
Control And Prevention ◽  
Health Organization

Human cytomegalovirus (CMV) is a highly prevalent herpesvirus worldwide. According to the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO), CMV infects people of all ages, and by the age of five, approximately one-third of children in the United States are infected. Although the infection is generally asymptomatic, it can cause severe disease in immunocompromised patients, transplant and transfusion recipients, as well as newborn neonates. The objective of this study is to systematically review published literature on CMV in the MENA region to estimate its incidence in the region and describe its epidemiological and clinical significance. The literature was searched through four scientific databases: PubMed, Scopus, Science Direct, and Web of Science. A total of 72 studies from 11 countries satisfied the inclusion criteria, covering a period from 1988–2019. The CMV IgG seroprevalence ranged from 8.7%–99.2% (SD = 38.95%). CMV incidence in these countries ranged between 1.22% and 77% in transplant and transfusion recipients, with an increase in incidence with advanced age. However, the incidence rate was unclear for congenital CMV due to the variability of the reporting. This review highlights the need for more robust and well-designed studies to better estimate CMV incidence in the MENA region, standardize diagnostic criteria, and consider prophylactic and pre-emptive treatments to limit the morbidity and mortality of the disease.

Pediatric Infectious Diarrhea and Dehydration

2018 ◽  
Author(s):  
John W. Martel ◽  
Scott McCorvey
Keyword(s):  
Hospital Admissions ◽  
The United States ◽  
World Health ◽  
Volume Depletion ◽  
Clinical Criteria ◽  
American Academy Of Pediatrics ◽  
Outpatient Visits ◽  
Control And Prevention ◽  
Uremic Syndrome ◽  
Health Organization

Diarrhea is a common emergency department (ED) complaint, leading to more than 1.5 million outpatient visits and 200,000 hospital admissions in the United States alone. Although concomitant dehydration also exists in some cases, there are no standard clinical criteria to aid in identifying those children who merit intravenous resuscitation. Current pediatric volume repletion guidelines are based primarily on the estimated degree of volume depletion per the World Health Organization, Centers for Disease Control and Prevention, and American Academy of Pediatrics criteria. These practice guidelines stratify patients into mild (3 to 5% volume depletion), moderate (5 to 10% volume depletion), and severe (> 10% volume depletion).  This review contains 5 figures, 9 tables, and 64 references. Key Words: Clostridium difficile, dehydration, diarrhea, gastroenteritis, hemolytic-uremic syndrome, pediatrics

scholarly journals Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Comprehensive Review

Diagnostics ◽  
2019 ◽  
Vol 9 (3) ◽  
pp. 91 ◽  
Author(s):  
Mateo Cortes Rivera ◽  
Claudio Mastronardi ◽  
Claudia Silva-Aldana ◽  
Mauricio Arcos-Burgos ◽  
Brett Lidbury
Keyword(s):  
Chronic Fatigue Syndrome ◽  
Age Of Onset ◽  
Chronic Fatigue ◽  
The United States ◽  
Myalgic Encephalomyelitis ◽  
World Health ◽  
Fatigue Syndrome ◽  
Control And Prevention ◽  
The Moment ◽  
Health Organization

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating chronic disease of unknown aetiology that is recognized by the World Health Organization (WHO) and the United States Center for Disease Control and Prevention (US CDC) as a disorder of the brain. The disease predominantly affects adults, with a peak age of onset of between 20 and 45 years with a female to male ratio of 3:1. Although the clinical features of the disease have been well established within diagnostic criteria, the diagnosis of ME/CFS is still of exclusion, meaning that other medical conditions must be ruled out. The pathophysiological mechanisms are unclear but the neuro-immuno-endocrinological pattern of CFS patients gleaned from various studies indicates that these three pillars may be the key point to understand the complexity of the disease. At the moment, there are no specific pharmacological therapies to treat the disease, but several studies’ aims and therapeutic approaches have been described in order to benefit patients’ prognosis, symptomatology relief, and the recovery of pre-existing function. This review presents a pathophysiological approach to understanding the essential concepts of ME/CFS, with an emphasis on the population, clinical, and genetic concepts associated with ME/CFS.

Keeping the flu at bay: Methods for detecting and containing infectious disease

2009 ◽  
Vol 7 (4) ◽  
pp. 9
Author(s):  
Atresha Karra, JD ◽  
Emily Cornette, JD
Keyword(s):  
Infectious Disease ◽  
United States ◽  
Disease Control ◽  
The United States ◽  
Communicable Diseases ◽  
World Health ◽  
Reporting Requirements ◽  
The World ◽  
Control And Prevention ◽  
Health Organization

This article focuses on the existing methods for tracking and restricting the spread of communicable diseases, both within United States borders and across nations. It will first describe the roles played by the United States’ Centers for Disease Control and Prevention and the World Health Organization and will then explore how communicable diseases across the world are identified and monitored. This will be followed by a discussion of US and world reporting requirements and methods. Finally, the article will discuss the tactics used by the United States to control the spread of disease.

scholarly journals The COVID States Project #75: Attitudes toward COVID-19 boosters before and after Omicron

2021 ◽  
Author(s):  
Roy H. Perlis ◽  
Matthew Baum ◽  
Kristin Lunz Trujillo ◽  
David Lazer ◽  
Alauna Safarpour ◽  
...  
Keyword(s):  
District Of Columbia ◽  
The United States ◽  
World Health ◽  
Vaccine Hesitancy ◽  
Dominant Form ◽  
The Us ◽  
Before And After ◽  
Control And Prevention ◽  
Health Organization ◽  
To Receive

Recognizing that the protection conferred by COVID-19 vaccines may wane over time, the US Centers for Disease Control and Prevention (CDC) has encouraged adults in the United States to receive booster shots that can augment their immunity to the virus. While the Biden administration sought to encourage all adults to receive boosters, the CDC initially authorized the shots only for higher-risk individuals. Subsequently, authorization was broadened to all adults, although only higher-risk individuals were encouraged to pursue boosters. Most recently, after substantial criticism, the CDC changed its language to encourage all adults to receive boosters.But regardless of the language, are US adults sufficiently convinced to seek booster shots? Will the same factors that contributed to COVID-19 vaccine hesitancy and vaccine resistance impact booster shots? The answers may have profound public health implications as the US enters the season during which respiratory viruses typically have the greatest impact, and the highly-transmissible Omicron variant rapidly becomes the dominant form of COVID-19, after being labeled a variant of concern by the World Health Organization on November 26th.Between November 3rd and December 3rd, 2021, the COVID States Project asked 22,277 adults in all 50 US states and the District of Columbia about their attitudes and behaviors regarding COVID-19. In particular, we asked about whether people are vaccinated or intend to be vaccinated, and whether they had sought booster shots or intend to seek a booster shot. In this brief report, we examine attitudes toward COVID-19 booster shots, and whether they differ across particular groups of people. Since the survey was ongoing when news about Omicron emerged in the US, we also take an initial look at whether these attitudes have begun to shift along with perceptions of the threat posed by COVID-19 subsequent to the November 26th announcement.

scholarly journals Global seasonal influenza mortality estimates: a comparison of three different approaches

2020 ◽  
Author(s):  
Vanessa Cozza ◽  
Harry Campbell ◽  
Howard H Chang ◽  
A Danielle Iuliano ◽  
John Paget ◽  
...  
Keyword(s):  
Eastern Mediterranean ◽  
Eastern Mediterranean Region ◽  
The United States ◽  
World Health ◽  
Service Research ◽  
Respiratory Mortality ◽  
Control And Prevention ◽  
Wide Variability ◽  
Health Organization ◽  
Mortality Estimates

Abstract Prior to updating global influenza-associated mortality estimates, the World Health Organization convened a consultation in July 2017 to understand differences in methodology and implications on results of three influenza mortality projects from the United States Centers for Disease Control and Prevention (CDC), the Netherlands Institute for Health Service Research (GLaMOR), and the Institute for Health Metrics and Evaluation (IHME). The expert panel reviewed estimates and discussed differences in data sources, analysis, and modeling assumptions. We performed a comparison analysis of the estimates. Influenza-associated respiratory death counts were comparable between CDC and GLaMOR; IHME estimate was considerably lower. The greatest country-specific influenza-associated mortality rate fold differences between CDC/IHME and between GLaMOR/IHME estimates were among countries in South-East Asia and Eastern Mediterranean region. The data envelope used for the calculation was one of the major differences (CDC and GLaMOR: all respiratory deaths; IHME: low respiratory infection deaths). With the assumption that there is only one cause of death for each death, IHME estimates a fraction of the full influenza-associated respiratory mortality that is measured by the other two groups. Wide variability of parameters was observed. Continued coordination between groups could assist with better understanding of methodological differences and new approaches to estimating influenza deaths globally.

scholarly journals Chemical threats in the EU Health Security Programme

2003 ◽  
Vol 7 (2) ◽  
Author(s):  
◽  
◽  
◽  
◽  
Keyword(s):  
Task Force ◽  
The United States ◽  
World Health ◽  
Global Health Security ◽  
Health Security ◽  
The World ◽  
Control And Prevention ◽  
Chemical Threats ◽  
Health Organization ◽  
The Eu

All projected tasks for the European Commission’s Task Force for Biological and Chemical Attacks (http://europa.eu.int/comm/health/ph/programmes/bio-terrorism/index_en.html) take both biological and chemical threats into account. The Task Force experts have compiled information from a series of valid lists of toxic threats, from bodies including the Organization for the Prohibition of Chemical Weapons (OPCW), the Australia Group* (AG), the World Health Organization (WHO), the United States Centers for Disease Control and Prevention (CDC), and others. A list of suspicious chemicals and toxins is being finalised by the Task Force, working with their counterparts in the Global Health Security Initiative of the G7+ countries (1).

Use of World Health Organization and CDC Growth Charts for Children Aged 0–59 Months in the United States (Excerpt)

2011 ◽  
Vol 2 (2) ◽  
pp. 11-13 ◽  
Keyword(s):  
United States ◽  
Expert Panel ◽  
Scientific Evidence ◽  
The United States ◽  
World Health ◽  
Growth Charts ◽  
Clinical Settings ◽  
International Growth ◽  
Control And Prevention ◽  
Health Organization

In 2006, the Centers for Disease Control and Prevention (CDC), the National Institutes of Health, and the American Academy of Pediatrics convened an expert panel to review scientific evidence and discuss the potential use of the new WHO growth charts in clinical settings in the United States. On the basis of input from this expert panel, CDC recommends that clinicians in the United States use the 2006 WHO international growth charts, rather than the CDC growth charts, for children aged <24 months (available at https://www.cdc.gov/growthcharts). The CDC growth charts should continue to be used for the assessment of growth in persons aged 2–19 years.

scholarly journals The effect of COVID-19 on global population and its fatality rate: Retrospective study by online database

2020 ◽  
Vol 72 ◽  
pp. 13-16
Author(s):  
Siva Prasad Palem ◽  
Hari Prasad Palem
Keyword(s):  
The United States ◽  
World Health ◽  
Fatality Rate ◽  
Online Database ◽  
Epidemic Disease ◽  
Online Data ◽  
Worldwide Population ◽  
Control And Prevention ◽  
Health Organization ◽  
Global Population

Objective: Coronavirus disease 2019 (COVID-19) is a current new virulent disease rising its transmission and fatality with each passing day in the worldwide population. COVID-19 is emerged as a respiratory infection and a suspicious origin of animals and transmission to human in Wuhan, China on December 2019. Later this, the virus was transmitted from person to person through droplets and contacts. The World Health Organization, Centers for Disease Control and Prevention, and the National Health Commission of the People’s Republic of China have taken immediate action to reduce transmission and fatality associated with COVID-19 as minimum as possible. However, action has failed to stop transmission of COVID-19 from China to other countries. Since there was no chain break of the virus, the chances are more to increase the case number and fatality. Hence, the study has been designed to perceive the current effect of COVID-19 on the global population and its fatality. The study also focused on review related to treatment for COVID-19. Material and Methods: Online database of epidemic disease COVID-19 cases number was collected from www.channelnewsasia.com on 7th April 2020. This data was used to observe the past and present circumstances in the global population and its fatality. The effect of treatment on COVID-19 was reviewed from the few databases of clinical trials (antiviral and antibacterial drugs). Results: The online data are used to observe a significant increase ratio of COVID-19 cases and its fatality rate in worldwide as well as country wise. The COVID-19 cases are high in the United States (27.5%), whereas the fatality rate is high in Italy (12.47%). The prevalence of COVID-19 is expected to be reaching 4 million by the end of April 2020 and the fatality rate also might be reached high. Conclusion: We have come to the conclusion that the effect of COVID-19 on the global population is significantly increased and the fatality rate also elevated (2.48% to 5.52%). The hydroxychloroquine-azithromycin combination treatment has shown significant improvement in patients with COVID-19 compared to treat with other drugs.

scholarly journals HIV Testing among Canadian Tuberculosis Cases from 1997 to 1998

2006 ◽  
Vol 17 (3) ◽  
pp. 165-168 ◽  
Author(s):  
Tara Harris ◽  
Linda Panaro ◽  
Melissa Phypers ◽  
Yogesh Choudhri ◽  
Chris P Archibald
Keyword(s):  
Risk Factors ◽  
Hiv Testing ◽  
Perceived Risk ◽  
Health Agency ◽  
The United States ◽  
World Health ◽  
Hiv Test ◽  
Number Of Patients ◽  
Control And Prevention ◽  
Health Organization

BACKGROUND: Recent evidence suggests a global rise in adult tuberculosis (TB) cases associated with HIV/AIDS. The World Health Organization, the United States Centers for Disease Control and Prevention, and the Public Health Agency of Canada advocate universal screening of all TB cases for HIV. The contribution of HIV to the TB burden in Canada remains unclear.METHODS: A retrospective cohort study was conducted of all TB cases reported in Canada from 1997 to 1998. The aim was to determine the proportion of patients that had an HIV test on record, and of these, the number of patients infected with HIV.RESULTS: From 1997 to 1998, 3767 TB cases were reported to the national TB surveillance system. In the present study, 3416 case records (90.7%) were included. The number of cases with a record of an HIV test was 736 (21.5%), and of these, 41.2% were tested within one month of TB diagnosis. Among the 703 cases with known HIV test results, the prevalence of HIV infection was 14.7%. Cases with an HIV test on record were more likely to have one or more risk factors for HIV, and also were more likely to be male, aged 15 to 49 years, of Aboriginal ethnicity, and to have smear-positive TB and both pulmonary and extrapulmonary disease at the time of diagnosis.DISCUSSION: These results suggest that HIV testing of TB patients is not universal, but rather selective, and is likely based on perceived risk factors for HIV as opposed to TB diagnosis alone.

Sign in / Sign up

Export Citation Format

Share Document